Cargando…

Emerging Role of Flavonoids as the Treatment of Depression

Depression is one of the most frequently observed psychological disorders, affecting thoughts, feelings, behavior and a sense of well-being in person. As per the WHO, it is projected to be the primitive cause of various other diseases by 2030. Clinically, depression is treated by various types of sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pannu, Arzoo, Sharma, Prabodh Chander, Thakur, Vijay Kumar, Goyal, Ramesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698856/
https://www.ncbi.nlm.nih.gov/pubmed/34944471
http://dx.doi.org/10.3390/biom11121825
_version_ 1784620377901629440
author Pannu, Arzoo
Sharma, Prabodh Chander
Thakur, Vijay Kumar
Goyal, Ramesh K.
author_facet Pannu, Arzoo
Sharma, Prabodh Chander
Thakur, Vijay Kumar
Goyal, Ramesh K.
author_sort Pannu, Arzoo
collection PubMed
description Depression is one of the most frequently observed psychological disorders, affecting thoughts, feelings, behavior and a sense of well-being in person. As per the WHO, it is projected to be the primitive cause of various other diseases by 2030. Clinically, depression is treated by various types of synthetic medicines that have several limitations such as side-effects, slow-onset action, poor remission and response rates due to complicated pathophysiology involved with depression. Further, clinically, patients cannot be given the treatment unless it affects adversely the job or family. In addition, synthetic drugs are usually single targeted drugs. Unlike synthetic medicaments, there are many plants that have flavonoids and producing action on multiple molecular targets and exhibit anti-depressant action by affecting multiple neuronal transmissions or pathways such as noradrenergic, serotonergic, GABAnergic and dopaminergic; inhibition of monoamine oxidase and tropomyosin receptor kinase B; simultaneous increase in nerve growth and brain-derived neurotrophic factors. Such herbal drugs with flavonoids are likely to be useful in patients with sub-clinical depression. This review is an attempt to analyze pre-clinical studies, structural activity relationship and characteristics of reported isolated flavonoids, which may be considered for clinical trials for the development of therapeutically useful antidepressant.
format Online
Article
Text
id pubmed-8698856
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86988562021-12-24 Emerging Role of Flavonoids as the Treatment of Depression Pannu, Arzoo Sharma, Prabodh Chander Thakur, Vijay Kumar Goyal, Ramesh K. Biomolecules Review Depression is one of the most frequently observed psychological disorders, affecting thoughts, feelings, behavior and a sense of well-being in person. As per the WHO, it is projected to be the primitive cause of various other diseases by 2030. Clinically, depression is treated by various types of synthetic medicines that have several limitations such as side-effects, slow-onset action, poor remission and response rates due to complicated pathophysiology involved with depression. Further, clinically, patients cannot be given the treatment unless it affects adversely the job or family. In addition, synthetic drugs are usually single targeted drugs. Unlike synthetic medicaments, there are many plants that have flavonoids and producing action on multiple molecular targets and exhibit anti-depressant action by affecting multiple neuronal transmissions or pathways such as noradrenergic, serotonergic, GABAnergic and dopaminergic; inhibition of monoamine oxidase and tropomyosin receptor kinase B; simultaneous increase in nerve growth and brain-derived neurotrophic factors. Such herbal drugs with flavonoids are likely to be useful in patients with sub-clinical depression. This review is an attempt to analyze pre-clinical studies, structural activity relationship and characteristics of reported isolated flavonoids, which may be considered for clinical trials for the development of therapeutically useful antidepressant. MDPI 2021-12-03 /pmc/articles/PMC8698856/ /pubmed/34944471 http://dx.doi.org/10.3390/biom11121825 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pannu, Arzoo
Sharma, Prabodh Chander
Thakur, Vijay Kumar
Goyal, Ramesh K.
Emerging Role of Flavonoids as the Treatment of Depression
title Emerging Role of Flavonoids as the Treatment of Depression
title_full Emerging Role of Flavonoids as the Treatment of Depression
title_fullStr Emerging Role of Flavonoids as the Treatment of Depression
title_full_unstemmed Emerging Role of Flavonoids as the Treatment of Depression
title_short Emerging Role of Flavonoids as the Treatment of Depression
title_sort emerging role of flavonoids as the treatment of depression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698856/
https://www.ncbi.nlm.nih.gov/pubmed/34944471
http://dx.doi.org/10.3390/biom11121825
work_keys_str_mv AT pannuarzoo emergingroleofflavonoidsasthetreatmentofdepression
AT sharmaprabodhchander emergingroleofflavonoidsasthetreatmentofdepression
AT thakurvijaykumar emergingroleofflavonoidsasthetreatmentofdepression
AT goyalrameshk emergingroleofflavonoidsasthetreatmentofdepression